The Food and Drug Administration’s recent approval of the drug ibrutinib offers a major new option for patients with chronic lymphocytic leukemia (CLL) who tried at least one prior therapy, physicians say.
Tag Archive for clinical trials
In prostate cancer – the most common cancer in men aside from skin cancer – scientists are working to answer some of the most basic questions about the disease while developing an array of new treatments.
Using the prostate-specific antigen (PSA) blood test, doctors are often able to detect prostate cancer at an early stage. But it remains difficult to determine which prostate cancers are likely to spread – and therefore require aggressive treatment – and which are either idle or slow-growing, and can be dealt with by “observation or active surveillance.” This uncertainty could result in unnecessary treatment for some patients.
NBC News’ Tom Brokaw, 74, revealed this week he has multiple myeloma, a cancer of the bone marrow. The disease, also known as plasma cell myeloma, will be diagnosed in more than 24,000 Americans this year.
Current lymphoma therapies are a far cry from the mustard gas used more than 50 years ago. More treatment options, including ones that may be more effective and less toxic, are being studied in ongoing clinical trials.
Breast cancer may develop in one part of the body, but it’s not just one disease. In fact, oncologists think of breast cancer as at least three different types of diseases.
Triple-negative breast cancer (TNBC) describes breast cancer cells that do not have estrogen, progesterone, or HER2 receptors. It makes up approximately 15 percent of all breast cancers and is typically more aggressive than the other two types, estrogen receptor-positive breast cancer and HER2-positive breast cancer.
“It may be the smallest group, but TNBC still represents thousands of women with breast cancer, so it is a very important group for us,” says Erica Mayer, MD, MPH, a medical oncologist at Dana-Farber’s Susan F. Smith Center for Women’s Cancers.
After a long period of slow progress, new knowledge about the genetics of ovarian cancer is leading to the development and testing of new therapies.
Researchers at the Susan F. Smith Center for Women’s Cancers will soon be launching several phase 3 clinical trials testing drugs known as PARP inhibitors for patients with platinum-sensitive recurrent ovarian cancer – tumors that initially responded to platinum-based chemotherapy agents but have shown evidence of regrowth at least six months after treatment. Phase 3 trials test drugs in large numbers of patients to evaluate the drugs’ effectiveness as well as safety. PARP inhibitors work by blocking one of the pathways by which tumor cells repair their damaged DNA.